TBPH Earnings Theravance Biopharma, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -0.10 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | 2.06 | 2026-03-23 | 10-K |
| FY 2025 | 2025-09-30 | 0.07 | 2026-03-23 | 10-K |
| FY 2025 | 2025-06-30 | 1.08 | 2026-03-23 | 10-K |
| Q1 2026 | 2025-03-31 | -0.27 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -1.15 | 2026-03-23 | 10-K |
| FY 2025 | 2024-09-30 | -0.26 | 2026-03-23 | 10-K |
| FY 2025 | 2024-06-30 | -0.34 | 2026-03-23 | 10-K |
| FY 2025 | 2024-03-31 | -0.24 | 2026-03-23 | 10-K |
| FY 2024 | 2023-12-31 | -1.00 | 2025-03-07 | 10-K |
| FY 2024 | 2023-09-30 | -0.17 | 2025-03-07 | 10-K |
| FY 2024 | 2023-06-30 | -0.28 | 2025-03-07 | 10-K |
| FY 2024 | 2023-03-31 | -0.35 | 2025-03-07 | 10-K |
| FY 2023 | 2022-12-31 | 11.85 | 2024-03-01 | 10-K |
| FY 2023 | 2022-09-30 | 12.14 | 2024-03-01 | 10-K |
| FY 2023 | 2022-06-30 | -0.11 | 2024-03-01 | 10-K |
| FY 2023 | 2022-03-31 | -0.34 | 2024-03-01 | 10-K |
| FY 2022 | 2021-12-31 | -2.87 | 2023-03-01 | 10-K |
| FY 2022 | 2021-09-30 | -0.48 | 2023-03-01 | 10-K |
| FY 2022 | 2021-06-30 | -0.80 | 2023-03-01 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.